Glenmark Pharmaceuticals receives final FDA approval for generic version of Pfizer’s Cleocin Hydrochloride capsule
The United States Food and Drug Administration (USFDA) has granted final approval to Glenmark Pharmaceuticals for Clindamycin Hydrochloride capsules.
The approved drug is a generic version of Pfizer Inc.’s Cleocin Hydrochloride capsule.
Clindamycin Hydrochloride capsules are used to treat infections of the lungs, skin, blood, female reproductive organs, and internal organs caused by bacteria. Patients who have had an allergic reaction to penicillin may be given this medication. Clindamycin is ineffective against colds, flu, and other viral infections.
Glenmark Pharmaceuticals Inc., USA will distribute Clindamycin Hydrochloride capsules USP in the United States.
Cleocin Hydrochloride capsules achieved annual sales of approximately $33.6 million, according to IQVIA sales data for the 12-month period ending January 2023.
The pharmaceutical company’s current portfolio includes 181 products approved for distribution in the United States and 47 ANDAs awaiting FDA approval.
Glenmark Pharmaceuticals is a global, innovation-driven pharmaceutical company with operations in specialty, generics, and over-the-counter (OTC).
In Q3 FY23, the company’s consolidated net profit increased 21.13% to Rs 290.76 crore on an 8% increase in net sales to Rs 3,392.24 crore compared to Q3 FY22.
The stock is currently trading at Rs 425.65 on the BSE, up 0.01%.